What is Psychedelic Assisted Psychotherapy?
Psychedelic Assisted Psychotherapy (PAP) is a clinical treatment framework in which patients receive psychoactive substances—typically psilocybin, MDMA, LSD, or ayahuasca—in controlled settings alongside preparation sessions, guided therapeutic support during the substance experience, and integration psychotherapy afterward. Unlike recreational use or purely pharmacological interventions, PAP positions the psychedelic experience itself as a catalyst for therapeutic insight, emotional processing, and behavioral change. The treatment is distinguished by its tripartite structure: preparatory sessions establish therapeutic alliance and intention, dosing sessions provide psychological support during altered states, and integration sessions help translate experiential insights into sustained life changes.
Origins & Lineage
Psychedelic substances have been used ceremonially for millennia by Indigenous cultures throughout the Americas, Africa, and Asia, though these traditional practices differ structurally from modern clinical PAP. The therapeutic application of psychedelics in Western medicine emerged in the 1950s when psychiatrist Humphry Osmond and biochemist Abram Hoffer began administering LSD to treat alcoholism in Saskatchewan, Canada. Between 1950 and 1965, over 1,000 clinical papers discussed approximately 40,000 patients treated with psychedelics for conditions including anxiety, depression, and addiction. Key early researchers included Stanislav Grof, who developed methods for LSD-assisted psychotherapy at the Maryland Psychiatric Research Center, and the Spring Grove experiments (1963-1976), which investigated psychedelic treatment for terminal cancer patients.
This first wave ended abruptly with the 1970 Controlled Substances Act in the United States, which classified most psychedelics as Schedule I substances, effectively halting research for two decades. The contemporary resurgence began in the 1990s when Rick Doblin founded the Multidisciplinary Association for Psychedelic Studies (MAPS) and researchers like Roland Griffiths at Johns Hopkins began rigorous clinical trials. The term “psychedelic-assisted psychotherapy” gained currency during this renaissance to distinguish evidence-based clinical practice from both recreational use and unstructured therapeutic contexts.
How It’s Practiced
Contemporary PAP follows standardized protocols developed through clinical trials. Treatment begins with 2-3 preparatory sessions where therapists (typically working in male-female pairs) assess patient history, establish trust, educate about substance effects, and cultivate therapeutic intentions. The dosing session occurs in a comfortable, home-like clinical environment with patients reclining on a couch, wearing eyeshades, and listening to curated instrumental music. Therapists remain present throughout the 4-8 hour session, offering minimal verbal intervention unless the patient initiates contact or appears distressed.
Therapeutic approach during dosing emphasizes non-directive presence rather than active interpretation. Therapists may offer physical reassurance, help patients stay present with difficult emotions, or guide breathing, but generally avoid cognitive analysis during the peak experience. The day after dosing, an initial integration session reviews the experience. Subsequent integration sessions over 6-12 weeks help patients process insights, work through surfaced material using conventional psychotherapy modalities, and implement behavioral changes.
Dosing protocols vary by substance: MDMA sessions typically involve 120-180mg with an optional supplemental dose; psilocybin dosing ranges from 20-30mg for high-dose protocols; ketamine treatments may involve multiple lower-dose sessions rather than single high-dose experiences.
Psychedelic Assisted Psychotherapy Today
As of 2026, PAP exists in three distinct contexts. First, clinical trials continue at major research institutions studying PTSD, treatment-resistant depression, end-of-life anxiety, eating disorders, and addiction. Second, licensed treatment centers offer ketamine-assisted psychotherapy legally, as ketamine remains available for off-label psychiatric use. Third, following regulatory approvals—MDMA-assisted therapy received FDA approval for PTSD treatment in 2024—a growing number of certified clinics offer legal PAP in the United States, Canada, Australia, and several European nations.
Retreats in jurisdictions where certain psychedelics remain legal (psilocybin truffles in the Netherlands, ayahuasca in Peru and Brazil) occupy a gray area between traditional ceremony and clinical practice. Training programs for therapists include MAPS’ MDMA Therapy Training Program, the California Institute of Integral Studies’ psychedelic-assisted therapies certificate, and Naropa University’s offerings. Professional organizations like the American Psychedelic Practitioners Association have emerged to establish practice standards.
Common Misconceptions
PAP is not simply administering a psychedelic drug and hoping for therapeutic benefit—the quality of therapeutic container, preparation, and integration distinguish it from both recreational use and purely pharmacological interventions. It is not a universal cure; approximately 30-40% of patients in clinical trials do not respond significantly, and some experience temporary psychological distress. PAP is not identical to Indigenous ceremonial use; while sharing some structural elements, clinical PAP emerges from Western psychotherapeutic traditions and lacks the cosmological frameworks of traditional practice.
The therapy is not currently available to anyone who requests it; contraindications include personal or family history of psychotic disorders, certain cardiovascular conditions, and concurrent use of some medications. PAP is not a single session cure—the most robust protocols involve months of preparation and integration. Finally, therapist training and certification matter significantly; the field has grappled with ethical violations and the importance of rigorous practitioner vetting.
How to Begin
Those seeking PAP should first determine what is legally available in their jurisdiction. In the United States, ketamine-assisted psychotherapy can be accessed through clinics like Field Trip Health or Mindbloom, though quality and therapeutic rigor vary significantly. For MDMA-assisted therapy for PTSD, the MAPS website maintains a directory of certified treatment centers. Prospective patients should verify that providers follow evidence-based protocols, employ licensed mental health professionals, and conduct thorough medical and psychological screening.
Education precedes participation. Michael Pollan’s “How to Change Your Mind” provides accessible history and context. “The Psychedelic Explorer’s Guide” by James Fadiman offers practical frameworks, while academic readers may consult the journal “Psychopharmacology” or anthologies like “Handbook of Medical Hallucinogens.” Organizations like the Multidisciplinary Association for Psychedelic Studies and the Usona Institute publish treatment manuals and research updates. Those considering traditional ceremonial contexts should research extensively, seek practitioners with verifiable lineage, and understand the significant cultural and practical differences from clinical PAP.